Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept 50 mg BIW in RA Sub-optimal Responders
NCT00115219Phase 4Completed
- Sponsor
- Amgen
- Start
- May 2005
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 4, randomised, double-blind trial of etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by Amgen. Primary endpoint: Proportion of subjects achieving a good or moderate DAS28 response at 12 weeks. Started May 2005; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00115219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115219.